Table 3 Implication of ECM in response to therapy for solid tumors
Cancer type | Study model | Treatment | Effect on ECM component | Reference |
|---|---|---|---|---|
Lewis lung carcinoma | In vitro—3D models | Doxorubicin | Diffusion of doxorubicin in tumor spheroids is hampered by the overexpression of LOX and LOXL2 | [153] |
Fibrosarcoma | ||||
Breast carcinoma | ||||
Pancreatic ductal adenocarcinoma | In vivo—murine model | Doxorubicin | Hyaluronidases reduce the hyaluronic acid content and increase the uptake of gemcitabine and doxorubicin | [156] |
Osteosarcoma | In vivo—murine model | Liposomal doxorubicin | Uptake of liposomal doxorubicin is improved by hyaluronidase treatment | [157] |
Small cell lung cancer | In vitro—cell lines | Etoposide | Expression of survival signals through ILK/Akt/NFkB determines the interaction between fibronectin and integrin β1, protecting against etoposide | [158] |
Ovarian carcinoma | In vitro—cell lines | Docetaxel | Silencing FAK in ovarian carcinoma sensitizes cells to docetaxel | [159] |
Colorectal carcinoma | In vitro—cell lines | 5-fluorouracil | Silencing FAK in colorectal carcinoma sensitizes the cells to 5-fluorouracil | [160] |